Click Here to Register »

2018 Agenda


  • Discovery & Preclinical Plenary Session


  • NK Cell CARs


    Dario Campana, MD, PhD

    Mrs Lee Kong Chian Chair in Advanced Cellular Therapy; Professor, Department of Pediatrics; Director, Division of Immunopathology and Cell Therapy
    National University of Singapore


  • Target Discovery for CAR-Ts and TCRs


    Laura Johnson, PhD

    Senior Director, Head Translational Medicine, Oncology Cell Therapy, GlaxoSmithKline


  • IDO plus Keytruda in Metastatic Myeloma


  • Early Clinical Data: Dual Targeting PDL1 and TGF Beta


    Julius Strauss, MD

    Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute


  • Investor Relations in Immunotherapy Plenary Session


  • Plenary Keynote: Evaluation and Forecast of the IO Space


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi


  • Venture Capitalist Perspective on the IO Landscape


    Bruce Booth, DPhil

    Partner, Atlas Venture


  • Investor Roundtable: The Role of IO within Large Pharma - Where Does it Stand?

    Moderator:

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline

    Panelists:


    Andrew Baum, MD

    Head of Global Healthcare; Managing Director, Equity Research, Citi


    Bruce Booth, DPhil

    Partner, Atlas Venture


    Ali Behbahani, MD

    Partner, New Enterprise Associates


    Simeon George, MD

    Partner, SR One Ltd


  • Translational Science and Biomarkers Plenary Session


  • The Role of Antibody Isotypes for Agonist Antibodies - ICOS


    Patrick Mayes, PhD

    Director & Early Development Leader, GlaxoSmithKline


  • Immune Suppression in The Tumor Micro-environment: The Adenosine Pathway


    Ian McCaffery, PhD

    VP, Translational Science, Corvus Pharmaceuticals


  • MORPHEUS Novel CIT Platform to Address Multiple Combinations


    William Grossman, MD, PhD

    Global Development Leader, Cancer Immunotherapy Combinations, Genentech


  • Update on Cancer Vaccination and Biomarkers of Response

    Lisa Butterfield
    Lisa Butterfield, PhD

    Professor of Medicine, Surgery and Immunology Director, UPCI Immunologic Monitoring and Cellular Products Laboratory / President, University of Pittsburgh / Society for Immunotherapy of Cancer (SITC)


  • Using TC Clonality Detecting Minimal Residual Disease


    Lanny Kirsch, MD

    SVP, Translational Medicine, Adaptive Biotechnologies


  • Use of Imaging Biomarkers for Immunotherapy


    Ron Korn, MD, PhD

    Founder, Chairman and Chief Medical Officer, Imaging Endpoints


  • Neoantigen Approaches for Biomarkers


  • Emerging Concepts for the Detection of Minimal Residual Disease using Liquid Biopsies


    Jonathan Wan, MD/PhD
    Student
    Cancer Research UK Cambridge Institute

2018 Agenda


  • New Trends & Collaborations Plenary Session


  • The BioCentury Report on Industry Trends


    Simone Fishburn, PhD

    Editor, BioCentury Innovations


  • The Endpoint News Report


    John D Carroll

    Editor-in-Chief, Endpoints News


  • Cancer Moonshot Progress


    Greg Simon, JD

    Director/ Former Executive Director,
    Biden Cancer Initiative/ Former White House Cancer Task Force  


  • Immuno-Oncology Progress in China


  • IO Emerging Technologies & Innovative Solutions Plenary Session

    This plenary will showcase companies that have technologies and solutions that will help stakeholders in the IO field advance developments to provide treatment for cancer patients.


  • Business Aspects Plenary Session


  • Summary of IO Deals


    Jeff Bockman, PhD

    Principal, SVP, Oncology Practice Head, Defined Health


  • Large Pharma Perspective on IO Licensing Technology


  • Payer Perspective: How Do We Arrive at a New Pricing Model for IO? How a Payer Thinks we should get Community Consensus on a Pricing Model


  • Panel: Talent Management for IO

    Moderator:


    Cissy Young, PhD, MBA

    Executive Director, Russell Reynolds Associates

    Panelists:


    Jasmine Ferrer, DPhil

    Sr Client Partner, Biotech & Pharma Sector, Korn Ferry International


    Adam Millinger

    Founding Partner, ProMotion Career Management

2018 Agenda


  • Clinical Aspects Plenary Session


  • Balancing Benefit and Toxicity From Immunotherapeutics: How to Make Recommendations to Patients


    Jeffrey Weber, MD, PhD

    Deputy Director, Laura and Isaac Perlmutter Cancer Center, Co-Director, Melanoma Program & Head of Experimental Therapeutics, NYU Langone Medical Center


  • Maintenance Therapy in NSCLC


    Naiyer Rizvi, MD

    Director, Thoracic Oncology & Immunotherapeutics in Medical Oncology, NY Presbyterian / Columbia University Medical Center


  • Keytruda in Combo with Chemo in NSCLC


  • Update on Tecentriq (Atezolizumab) in Bladder Cancer


    Jonathan Rosenberg, MD

    Medical Oncologist, Memorial Sloan Kettering Cancer Center


  • The Role of PDL1 on Survival


  • FDA Viewpoint: Update on the Bladder Cancer Data with the Implications for Atezolizumab OS Failure for Both its Approval and That of Other Agents in Bladder Cancer


  • Changing Treatment Landscape in NSCLC


  • Pembrolizumab as a Broad Spectrum Anticancer Therapy Both as Mono and Combination Therapy


    Roy Baynes, MD, PhD

    SVP & Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories


  • Differences in Long Term Benefit Between Classes of Checkpoint Modulators


  • Trout Group Situation Room

    2017 trout group


  • Executive Fireside Chat

    Invited guest:

    George Yancopoulos, MD, PhD
    President & CSO, Regeneron


  • The Investor Lifecycle - How to Maneuver at Each Stage of Financing from Seed to Public Market


  • Panel: Immuno-Oncology CEOs Checking The Target


  • IO CEO Fireside Chats